Drug intelligence / Profile preview

NuCerin

Development stage: Unknown
Lead developer: Shaperon
Modality: Small Molecules
Administration: Oral

Overview

**NuCerin** is an investigational oral formulation of HY209, a small-molecule sodium taurodeoxycholate program developed by Shaperon for Alzheimer's disease. HY209 is a GPCR19/TGR5 agonist designed to modulate GPCR19-P2X7 signaling and suppress inflammasome-associated neuroinflammation; preclinical 5xFAD mouse data reported reduced amyloid-beta plaque burden and improved cognitive outcomes. NuCerin completed a Phase 1 study in healthy adults in South Korea and is being jointly developed with Kukjeon, with Hudson Therapeutics supporting global development and partnering activities. ([alz-journals.onlinelibrary.wiley.com](https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.086687))

Other names: Nucerin

Targets

GPBAR1 (G protein-coupled bile acid receptor 1)

Beyond the preview

Go deeper on NuCerin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuCerin.

Explore the full profile